Human cloning and human genome editing are often discussed as though they were neighboring versions of the same technology. They solve different biological problems. Cloning by somatic cell nuclear transfer seeks to restart development using the nuclear genome of an existing cell. Genome editing changes selected DNA sequences. Neither approach provides a complete specification of an adult human body, brain, or personal history.
That distinction matters because the scientific challenge grows rapidly as the goal moves from copying a nuclear genome toward reproducing a person with specified anatomy, physiology, behavior, and cognition. Modern biotechnology has achieved remarkable control at the level of individual cells and selected genetic targets. Whole-organism development remains far less predictable.
The current landscape spans human cloning research, somatic and heritable genome editing, developmental barriers between genotype and phenotype, and the technologies relevant to the broader Molecular Mining research mission.
What “human cloning” can mean
The word cloning covers several distinct activities. Molecular cloning copies DNA fragments. Cell cloning produces genetically related cell populations. Therapeutic or research cloning uses nuclear-transfer techniques to derive cells for study. Reproductive cloning would use a reconstructed embryo to establish a pregnancy and produce a live-born organism.
The best-known reproductive-cloning method in mammals is somatic cell nuclear transfer, or SCNT. In broad terms, SCNT places the nucleus of a differentiated cell into an egg whose own nuclear material has been removed. The central biological task is reprogramming: an adult cell nucleus must regain a developmental state capable of directing embryogenesis.
Dolly the sheep demonstrated that a nucleus from an adult mammalian cell can retain the genetic information needed to support development. Subsequent work extended SCNT across numerous mammalian species. A landmark 2018 study reported cloned cynomolgus macaques, showing that SCNT could work in a non-human primate when major reprogramming barriers were addressed.1
SCNT copies a nuclear genome, not an adult person
A successful SCNT offspring can be highly similar to the nuclear donor genetically. Genetic identity at the level of nuclear DNA still leaves several sources of biological difference.
The egg contributes cytoplasm, organelles, regulatory molecules, and mitochondrial DNA. Embryonic development introduces epigenetic remodeling, stochastic cell-state decisions, placental effects, uterine influences, nutrition, disease exposures, and many other environmental variables. Postnatal growth adds another long sequence of contingencies. A nuclear-genome copy therefore does not imply perfect anatomical or physiological identity.
The distinction becomes even larger for the nervous system. Memories, learned skills, language, habits, and much of an individual’s neural connectivity are products of development and experience. A clone born from the nuclear DNA of an adult would begin its own developmental history. Genetic similarity would offer no mechanism for transferring the donor’s memories.
The central barrier in cloning: epigenetic reprogramming
SCNT requires a differentiated nucleus to abandon a cell-specific regulatory program and support embryonic development. This transition is difficult. DNA methylation, histone modifications, chromatin structure, genomic imprinting, and other regulatory states can persist in forms that interfere with normal gene activation.
Research on mammalian cloning has repeatedly identified incomplete epigenetic reprogramming as a major source of developmental failure. A 2025 study of mouse SCNT embryos described distinct pre-implantation and post-implantation epigenetic barriers, including abnormal chromatin states and disrupted imprinting.2 A 2026 review of somatic-cell reprogramming likewise places epigenetic remodeling at the center of current efforts to reverse differentiated cell states.3
These problems help explain why cloning efficiency can remain low even when a transferred nucleus contains an intact genome. Development depends on when genes become accessible, how regulatory programs change over time, and whether extraembryonic tissues and the embryo remain coordinated.
What has been achieved with human SCNT
Human SCNT has produced scientifically important results in cell biology. In 2013, researchers reported human embryonic stem-cell lines derived from SCNT embryos.4 That work demonstrated that a human somatic nucleus could be reprogrammed through an oocyte environment sufficiently to generate pluripotent stem cells.
This achievement should be interpreted at the correct biological scale. Deriving pluripotent cells establishes the feasibility of nuclear reprogramming for a cellular research objective. A live birth requires successful implantation, placental development, fetal growth, birth, and long-term health across an integrated organism. No verified human reproductive clone has been reported.
Primate cloning also remains technically demanding. Genome-scale analyses published after the first macaque cloning successes continue to identify developmental roadblocks, low efficiency, and neonatal risks in primate SCNT.5
Genome editing solves a different problem
Genome editing changes selected sequences within DNA. CRISPR-Cas systems, base editors, prime editors, and related approaches can alter genes with a level of targeting that was difficult to imagine during the early era of mammalian cloning.
Human genome editing is already a clinical reality in a restricted and carefully controlled sense. The U.S. Food and Drug Administration approved CASGEVY, an ex vivo CRISPR/Cas9-edited cell therapy for sickle cell disease, in 2023 and later expanded its indication; in July 2026 the FDA extended eligibility to patients as young as two years for specified sickle cell disease and transfusion-dependent β-thalassemia indications.6
CASGEVY illustrates the power of somatic genome editing. A patient’s blood-forming stem cells are edited outside the body and returned as a therapy. The genetic intervention is directed toward a defined disease mechanism in a defined cell population. It does not redesign a person across every tissue.
Somatic, germline, and heritable editing
Human genome editing becomes easier to reason about when three categories are separated:
- Somatic editing changes cells in an existing person. The edit is intended to treat that individual and is generally not transmitted through reproduction.
- Germline research can involve gametes, embryos, or precursor cells without establishing a pregnancy.
- Heritable genome editing involves genetic changes that can pass to future generations.
The World Health Organization recognizes these categories and emphasizes stronger safety, ethical, and governance concerns for heritable applications. WHO guidance continues to treat clinical use of heritable human genome editing as premature.7 The International Society for Stem Cell Research likewise places embryo-related and reproductive research within a framework of rigorous oversight, transparency, and scientific justification.8
Why editing a few genes cannot specify a person
Single-gene disorders provide the clearest setting for targeted genome editing because the causal architecture can be relatively well defined. Many human traits have a radically different structure. Height, facial morphology, body composition, disease susceptibility, cognition, and behavior can involve large numbers of variants with small effects, interactions among loci, regulatory networks, developmental timing, and environmental influence.
A list of trait-associated variants is therefore an incomplete recipe for a phenotype. Genome-wide association studies can estimate statistical relationships across populations. Translating those associations into reliable design rules for one individual requires causal knowledge about cell types, developmental stages, regulatory context, pleiotropy, and gene–environment interaction.
Genome editing also introduces its own technical uncertainties. Depending on the method and biological setting, researchers must consider unintended sequence changes, larger genomic alterations, mosaicism, delivery, cell-type specificity, and the consequences of changing genes that participate in multiple biological pathways. Increasing the number of coordinated edits compounds the validation problem.
Why development matters as much as DNA
An adult organism is the outcome of a process. During development, cells divide, differentiate, migrate, communicate, form spatial patterns, and construct tissues whose functions depend on interactions with other tissues. The genome participates throughout this process, while regulatory states and physical environments influence how that information is used.
For a technology whose eventual aim is a human organism with specified characteristics, developmental biology becomes a core engineering constraint. The relevant questions include cell fate, morphogenesis, organogenesis, vascularization, innervation, immune development, endocrine coordination, placental biology, and maturation.
This is where cloning and gene editing converge conceptually. SCNT demonstrates that an adult nuclear genome can sometimes be returned to an embryonic developmental program. Gene editing demonstrates that selected sequences can be changed with increasing precision. A future system capable of specifying a whole person would require far greater control over the developmental program connecting those genetic states to tissues and organs.
Cloning and gene editing in the context of human reconstruction
Consider a future system that begins with data about an existing person: video, photographs, voice, medical imaging, genomic data, molecular measurements, and physiological records. Cloning and genome editing could address only part of the resulting reconstruction problem.
| Scientific layer | What current technology can contribute | Major remaining gap |
|---|---|---|
| Nuclear genome | SCNT can replicate a donor nuclear genome in animals; sequencing can characterize human genomes. | Reliable whole-organism reprogramming and development in humans. |
| Selected DNA variants | Somatic CRISPR editing can make targeted therapeutic changes. | Safe, validated coordination of many edits and their organism-wide effects. |
| Epigenetic state | Reprogramming research can erase or reshape portions of somatic epigenetic memory. | Predictable control of developmental regulatory states across tissues. |
| Anatomy and phenotype | Imaging and computational models can measure many observable characteristics. | Causal mapping from measurements to developmental instructions. |
| Brain and behavior | Genetics and neuroscience can explain selected mechanisms and statistical influences. | Reconstruction of individual neural state, learned information, and memory. |
| Maturation | Cell and tissue engineering can produce selected biological structures. | Safe coordinated maturation of a complete human organism. |
The difference between genetic resemblance and personal identity
A high-fidelity biological copy raises questions that extend beyond DNA. A monozygotic twin already demonstrates that extremely close genetic similarity can coexist with distinct memories, personalities, medical histories, and subjective lives. A clone produced years later would experience an even more different developmental environment.
For this reason, any serious discussion of human reconstruction needs separate validation criteria. One criterion could measure genomic similarity. Others could measure anatomy, physiology, immune function, behavior, cognition, and memory. “The same person” is a stronger claim than any one of these measurements can establish.
What progress would change the field
Several advances would materially alter the scientific landscape:
- higher-fidelity epigenetic reprogramming with much lower developmental failure rates;
- causal models linking genetic and regulatory variation to whole-organism phenotypes;
- reliable multiplex editing with comprehensive validation of large-scale genomic integrity;
- better human developmental maps across cell types, tissues, and time;
- integrated tissue engineering capable of vascularization, innervation, immune compatibility, and endocrine coordination;
- quantitative models connecting external phenotype measurements to developmental mechanisms;
- deeper understanding of neural development, memory formation, and the biological basis of persistent individual traits.
Progress in these areas would affect medicine long before it enabled any comprehensive reconstruction of a human. Regenerative therapies, disease modeling, reproductive biology, organ engineering, and personalized treatment all benefit from the same underlying knowledge.
Where the science stands
Human cloning remains an unresolved reproductive technology. SCNT has demonstrated nuclear reprogramming in many mammals, produced cloned macaques, and generated human pluripotent stem cells. Its developmental reliability remains limited, especially in primates.
Human genome editing has already crossed into regulated medicine through somatic therapies. Heritable editing carries substantially greater biological and ethical uncertainty. Editing a handful of loci also occupies a very different scale from specifying a complete human phenotype.
The most important frontier lies in integration: connecting genome, epigenome, cell state, development, anatomy, physiology, and neural function within one predictive framework. That is also the frontier where cloning research, genome editing, human phenomics, developmental biology, regenerative medicine, and computational modeling begin to form a single research program.
References
- Liu Z, et al. Cloning of Macaque Monkeys by Somatic Cell Nuclear Transfer. Cell. 2018.
- Zhang and colleagues. Efficient Somatic Cell Nuclear Transfer by Overcoming Both Pre- and Post-Implantation Epigenetic Barriers. Advanced Science. 2025.
- Liao Z-E, et al. Somatic cell reprogramming into stem cells: approaches, mechanisms, and therapeutic applications. 2026.
- Tachibana M, et al. Human embryonic stem cells derived by somatic cell nuclear transfer. Cell. 2013.
- Moura MT. Genome-Scale Analyses Reveal Roadblocks to Monkey Cloning. Cell Reprogramming. 2024.
- U.S. Food and Drug Administration. CASGEVY. Current FDA product information and approval history.
- World Health Organization. Human genome editing. Current overview and governance position.
- International Society for Stem Cell Research. Guidelines for Stem Cell Research and Clinical Translation. 2025 update.